Dublin, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
The Global Active Pharmaceutical Ingredients CDMO Market, valued at USD 96.98 Million in 2024, is projected to experience a CAGR of 6.10% to reach USD 138.35 Million by 2030
An Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides comprehensive development and manufacturing services for APIs on a contract basis, assisting pharmaceutical firms with drug substance synthesis, process optimization, scalable production, and regulatory compliance.
The market's growth is primarily driven by increasing pharmaceutical research and development investments, the escalating global prevalence of chronic diseases necessitating new therapies, and the growing complexity of drug molecules.
Key Market Drivers
The robust pharmaceutical research and development pipeline, along with consistent new drug approvals, significantly drives the Global Active Pharmaceutical Ingredients CDMO Market. Substantial industry investment in novel therapies necessitates specialized API development and manufacturing expertise. According to the International Federation of Pharmaceutical Manufacturers & Associations, global pharmaceutical R&D expenditure reached USD 204 billion in 2023, underscoring this commitment to innovation and growth.
This sustained investment fuels demand for CDMOs capable of supporting complex early-stage development through commercial scale production. The global API manufacturing landscape features geographically diversified capabilities, crucial for supply chain resilience. For instance, according to the Pacific Forum, in 2022, India housed 18% of global API manufacturing facilities, demonstrating the importance of specialized centers in meeting worldwide demand.
Key Market Challenges
A significant challenge impeding the growth of the Global Active Pharmaceutical Ingredients CDMO Market involves maintaining adequate transparency and control over outsourced production processes. This difficulty can lead to struggles in pinpointing the origin of manufacturing issues, navigating complex supply chains, and potentially causing a loss of critical knowledge for the contracting pharmaceutical company. Without clear visibility and stringent control, pharmaceutical firms face heightened risks regarding product quality and regulatory compliance.
Key Market Trends
The rising outsourcing of biologics and advanced therapies production represents a pivotal trend in the Global Active Pharmaceutical Ingredients CDMO Market. As pharmaceutical companies increasingly focus on complex biopharmaceuticals, including monoclonal antibodies, cell, and gene therapies, the specialized expertise and infrastructure required for their development and manufacturing often necessitate external partnerships.
These advanced modalities demand sophisticated facilities, stringent quality control, and specialized technical personnel that many pharmaceutical companies prefer to outsource to dedicated CDMOs. The U. S. Food and Drug Administration (FDA) reported that in 2023, the Center for Biologics Evaluation and Research (CBER) approved 22 new Biologics License Applications (BLAs), nearly doubling the approvals from 2021 and 2022, underscoring the expanding pipeline in this segment.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $96.98 Million |
| Forecasted Market Value (USD) by 2030 | $138.35 Million |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
Report Scope:
Key Market Players Profiled:
- Cambrex Corporation
- Thermo Fisher Scientific, Inc.
- Recipharm AB
- Corden Pharma International GmbH
- Samsung Biologics Co., Ltd.
- Lonza Group Ltd.
- Siegfried Holding AG
- Piramal Pharma Limited
- AbbVie Inc.
- Catalent, Inc.
By Molecule Type:
- Small Molecule
- Large Molecule
By Synthesis:
- Biotech
- Synthetic
By Drug Type:
- Innovative
- Generics
By Workflow:
- Clinical
- Commercial
By Application:
- Cardiology
- Oncology
- Ophthalmology
- Neurology
- Orthopedic
- Other
By Region:
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
For more information about this report visit https://www.researchandmarkets.com/r/vk9co2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
